OSE Immunotherapeutics Welcomes Thomas Gidoin as CFO
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) proudly announces the appointment of Thomas Gidoin as its new Chief Financial Officer. Thomas brings with him over 15 years of extensive experience in capital markets, financial strategies, and corporate governance, making him a valuable addition to the Executive Committee.
Thomas Gidoin's Extensive Background
Thomas Gidoin is not a stranger to the biopharmaceutical arena. With a proven track record in both private and public sectors, he has excelled in strategic financial leadership roles. Prior to joining OSE Immunotherapeutics, Thomas served as the Chief Financial Officer at Advesya, a private biotech company focused on oncology and autoimmune diseases. His tenure there was preceded by an impactful eight years at GenSight Biologics, a publicly traded company that specializes in gene therapies for neurodegenerative retinal diseases.
At GenSight, he spearheaded financing strategies from their Series B funding to their IPO, along with managing several follow-on transactions and structured finance opportunities. Before his role at GenSight, Thomas was Vice President of Finance at DBV Technologies, overseeing corporate finances and contributing to public offerings and private placements. His career commenced in audit at Ernst & Young in Paris, offering him a strong financial foundation.
Transition to OSE Immunotherapeutics
Thomas takes over from Anne-Laure Autret-Cornet, ushering in a new era of financial leadership within OSE Immunotherapeutics. His expertise arrives at a crucial moment, as the company aims to advance its late-stage assets and leverage its innovative research platform, which is fundamental for its growth strategy.
Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, expressed enthusiasm regarding Thomas's arrival, stating:
“As Thomas joins us, his profound experience in biotech capital markets and financial planning equips us with the leadership needed to drive our innovation forward. His strategic vision aligns perfectly with our goals of developing late-stage assets and enhancing our operational focus.”
Vision for the Future
Expressing his excitement, Thomas Gidoin remarked:
“Joining OSE Immunotherapeutics at this pivotal moment is truly exhilarating. With two late-stage assets focused on oncology and inflammation, combined with our innovative research platform, I see tremendous opportunities to create significant long-term value for the company and its stakeholders.”
Company Overview
OSE Immunotherapeutics is a pioneering biotech firm dedicated to developing first-in-class products in immuno-oncology and immuno-inflammation. The company strives to address today's unmet medical needs through collaborations with leading academic institutions and biopharmaceutical companies, aiming to bring transformative medicines to market for patients with serious medical conditions. With strong foundations in Nantes and Paris, OSE Immunotherapeutics is publicly traded on Euronext.
Frequently Asked Questions
Who is the new Chief Financial Officer of OSE Immunotherapeutics?
Thomas Gidoin has been appointed as the new Chief Financial Officer.
What previous experience does Thomas Gidoin have?
Thomas brings over 15 years of experience, including leadership roles at Advesya and GenSight Biologics.
What does OSE Immunotherapeutics focus on?
The company focuses on developing first-in-class assets in immuno-oncology and immuno-inflammation.
Where is OSE Immunotherapeutics based?
OSE Immunotherapeutics operates between Nantes and Paris and is listed on Euronext.
How does Thomas Gidoin plan to contribute to OSE Immunotherapeutics?
Thomas intends to leverage his extensive experience to enhance financial strategies and support the company’s growth and innovation initiatives.
